韩国真实世界研究:BIC/FTC/TAF与DTG/3TC对初治HIV感染者血脂变化的比较
韩国单中心回顾性队列纳入194例初治HIV感染者,比较BIC/FTC/TAF与DTG/3TC启动后2年血脂变化。DTG/3TC组LDL-C升幅显著更小(β=-8.03,P=0.035),TC/HDL-C比值有改善趋势(β=-0.19,P=0.094),甘油三酯无显著差异。
要点
- 初治HIV感染者中,DTG/3TC较BIC/FTC/TAF的LDL-C升幅显著更小。
- DTG/3TC组TC/HDL-C比值呈改善趋势,但未达统计学显著性。
- 甘油三酯两组间无显著时间交互差异。
核心结论
- 在初治HIV感染者中,DTG/3TC较BIC/FTC/TAF表现出更有利的血脂变化,LDL-C升幅显著更小。
- TC/HDL-C比值在DTG/3TC组呈改善趋势,但未达统计学显著性。
研究设计与样本
- 韩国首尔国立医疗中心2012年1月至2024年3月医疗记录的回顾性队列研究。
- 最终分析纳入194例初治HIV感染者,137例(70.6%)启动BIC/FTC/TAF,57例(29.4%)启动DTG/3TC。
- 排除使用降脂药物者及有ASCVD病史者,合并乙型/丙型肝炎感染者纳入并作为协变量调整。
- 采用线性混合模型比较不同ART方案启动后2年内的血脂变化。
主要发现
- DTG/3TC组LDL-C随时间升幅显著小于BIC/FTC/TAF组(ART-by-time交互:β=-8.03,P=0.035)。
- TC/HDL-C比值在DTG/3TC组呈改善趋势(β=-0.19,P=0.094)。
- 甘油三酯水平保持稳定,无显著ART-by-time交互(β=17.60,P=0.271)。
临床怎么用
- 对有心血管危险因素的初治HIV感染者,ART方案选择时可参考DTG/3TC较BIC/FTC/TAF LDL-C升幅更小的真实世界证据。
局限性
- 回顾性单中心队列设计,样本量有限(共194例,DTG/3TC组57例)。
- TC/HDL-C比值改善趋势未达统计学显著性(P=0.094)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advances in antiretroviral therapy (ART) have shifted the focus of HIV management towards metabolic comorbidities such as atherosclerotic cardiovascular disease (ASCVD). However, real-world data comparing lipid profile changes, key determinants of ASCVD, between bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir/lamivudine (DTG/3TC) remain limited. METHODS: A retrospective cohort study was conducted using medical records from the National Medical Center, Seoul, South Korea, from January 2012 to March 2024. Lipid profiles were analysed over 2 years following initiation of BIC/FTC/TAF or DTG/3TC in treatment-naïve people living with HIV (PLH). Individuals receiving lipid-lowering agents and a previous history of ASCVD were excluded. People with hepatitis B and/or C virus infection were included, and infection status was adjusted for as a covariate along with alanine aminotransferase and aspartate aminotransferase. A linear mixed model was applied to compare lipid profiles between the different ART regimens over time. RESULTS: A total of 194 treatment-naïve PLH were included in the final analysis: 137 (70.6%) initiated BIC/FTC/TAF and 57 (29.4%) initiated DTG/3TC. Over 2 years, longitudinal analysis showed that PLH receiving DTG/3TC had significantly smaller LDL cholesterol increases over time compared to BIC/FTC/TAF (ART-by-time interaction: β = -8.03, P = 0.035). The TC/HDL-C ratio showed a trend towards improvement in the DTG/3TC group (β = -0.19, P = 0.094). Triglyceride levels remained stable with no significant ART-by-time interaction (β = 17.60, P = 0.271). CONCLUSIONS: DTG/3TC demonstrated more favourable lipid changes than BIC/FTC/TAF in treatment-naïve individuals, with significantly smaller LDL cholesterol increases and a trend towards an improved TC/HDL ratio over time. These findings may be informative during the ART selection especially for PLH with cardiovascular risk factors.
引用
- Lim SY, Chin B, Kim MK, et al. Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea. J Antimicrob Chemother. 2025. PMID: 40748688. doi:10.1093/jac/dkaf213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。